These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26904699)

  • 41. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
    Coiffier B; Altman A; Pui CH; Younes A; Cairo MS
    J Clin Oncol; 2008 Jun; 26(16):2767-78. PubMed ID: 18509186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
    Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
    Spina M; Nagy Z; Ribera JM; Federico M; Aurer I; Jordan K; Borsaru G; Pristupa AS; Bosi A; Grosicki S; Glushko NL; Ristic D; Jakucs J; Montesinos P; Mayer J; Rego EM; Baldini S; Scartoni S; Capriati A; Maggi CA; Simonelli C;
    Ann Oncol; 2015 Oct; 26(10):2155-61. PubMed ID: 26216382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
    Mughal TI; Ejaz AA; Foringer JR; Coiffier B
    Cancer Treat Rev; 2010 Apr; 36(2):164-76. PubMed ID: 20031331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of tumor lysis syndrome with the highest known uric acid level.
    Ozkan G; Ulusoy S; Sönmez M; Kaynar K; Karagülle M
    Ren Fail; 2010; 32(7):895-8. PubMed ID: 20662707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention and management of tumor lysis syndrome in adults with malignancy.
    Sarno J
    J Adv Pract Oncol; 2013 Mar; 4(2):101-6. PubMed ID: 25031988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The management of tumor lysis syndrome.
    Rampello E; Fricia T; Malaguarnera M
    Nat Clin Pract Oncol; 2006 Aug; 3(8):438-47. PubMed ID: 16894389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
    Jeha S; Pui CH
    Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A retrospective review of rasburicase utilization in pediatric and adult patients across a large health system.
    Kamel A; Sanders M; Dyk H; Hamilton T
    J Oncol Pharm Pract; 2024 May; ():10781552241253214. PubMed ID: 38794946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
    Teo WY; Loh TF; Tan AM
    Ann Acad Med Singap; 2007 Aug; 36(8):679-83. PubMed ID: 17767339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor lysis syndrome in solid tumors.
    Mott FE; Esana A; Chakmakjian C; Herrington JD
    Support Cancer Ther; 2005 Apr; 2(3):188-91. PubMed ID: 18628171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor lysis syndrome in elderly.
    Pumo V; Sciacca D; Malaguarnera M
    Crit Rev Oncol Hematol; 2007 Oct; 64(1):31-42. PubMed ID: 17658268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Needle in the Haystack: A Rare Case of Spontaneous Tumor Lysis in Newly Diagnosed Chronic Lymphocytic Leukemia Unmasked by Acute Renal Failure.
    Desai M; Parsi M; Potdar R; Sanjay R
    Cureus; 2020 Oct; 12(10):e11279. PubMed ID: 33274154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Rare Syndrome in a Rare Carcinoma: A Case of Spontaneous Tumor Lysis Syndrome in Small-Cell Liver Carcinoma.
    Aina DA; Erwin A; Li E; Manam R
    Cureus; 2023 Feb; 15(2):e35455. PubMed ID: 36994306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
    Serling-Boyd N; Quandt Z; Allaudeen N
    Mol Clin Oncol; 2017 Apr; 6(4):589-592. PubMed ID: 28413674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.